Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Y Liu, SK Barta - American journal of hematology, 2019 - Wiley Online Library
Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
Double hit and double expressors in lymphoma: definition and treatment
PA Riedell, SM Smith - Cancer, 2018 - Wiley Online Library
Emerging biologic subsets and new prognostic markers are significantly and adversely
affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas …
affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas …
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
JA Snowden, I Sánchez-Ortega… - Bone marrow …, 2022 - nature.com
For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …
Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance …
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study,
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
N Liebers, J Duell, D Fitzgerald, A Kerkhoff… - Blood …, 2021 - ashpublications.org
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in
combination with bendamustine and rituximab (pola-BR) for patients with refractory or …
combination with bendamustine and rituximab (pola-BR) for patients with refractory or …
Outcomes of patients with double-hit lymphoma who achieve first complete remission
DJ Landsburg, MK Falkiewicz, J Maly… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival
following disease relapse. Some patients with DHL undergo consolidative autologous stem …
following disease relapse. Some patients with DHL undergo consolidative autologous stem …
Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
P Sesques, NA Johnson - Blood, The Journal of the American …, 2017 - ashpublications.org
High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements,
so-called “double-hit” lymphomas (HGBL-DH), are aggressive lymphomas that form a …
so-called “double-hit” lymphomas (HGBL-DH), are aggressive lymphomas that form a …
How I treat double-hit lymphoma
JW Friedberg - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
The 2016 revision of the World Health Organization (WHO) classification for lymphoma has
included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed …
included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed …
Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
For relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL), consolidation with
autologous hematopoietic cell transplantation (auto-HCT) is a standard option. With the …
autologous hematopoietic cell transplantation (auto-HCT) is a standard option. With the …